
oct pm et
summari compani develop da vinci surgic system use advanc robot
computer visual technolog minimally-invas surgeri
price-to-earnings oper ep
risk assess base highli competit
environ robot surgeri new competitor
enter market requir complianc
foreign regul potenti legal liabil
injuri may result use compani
jan ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct stock trade
expect sale rise
respect follow
growth like driven
sustain grow adopt robot
gener surgeri particularli colorect
bariatr procedur hernia repair thorac
procedur growth gener surgeri use
stimul continu
effort improv expand portfolio
gener surgeri tool includ new
product sureform stapler
fulli launch vessel sealer
extend launch
also see grow exposur asia
key driver futur procedur growth
expect procedur volum increas
june instal
system base compar
instrument accessori revenu per
procedur rose slightli
vs
custom buy pattern look
gross margin improv
due
lower cost improv manufactur
find share current trade
ep estim vs
five-year rang
expens support momentum
volum growth howev also
expect increas competit new
entrant numer competitor work
bring advanc surgic robot market
competitor probabl furthest along
obtain fda
approv senhanc system octob
sale began phase
launch da vinci sp
platform believ system
signific advantag prior model
could drive long-term growth initi
market da vinci sp urolog surgeri
head neck surgeri well colorect
risk recommend target price
includ lower procedur volum growth
project increas competit pressur
target price assum
multipl ep
estim peer
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview intuit surgic design da vinci surgic system product
incorpor advanc robot computer visual technolog improv abil
surgeon perform complex minimally-invas procedur year-end compani
instal base da vinci surgic system year-end
respect surgeon use compani technolog complet estim
surgic procedur variou type includ urolog gynecolog cardiothorac gener surgeri
surgic procedur
commerci four gener da vinci surgic system fourth gener includ
da vinci da vinci xi da vinci surgic system consist surgeon consol patient-sid
cart high-perform vision system proprietari wrist instrument system translat
surgeon natur hand movement instrument control consol correspond
micro-mov instrument posit insid patient small punctur incis port
system aim give surgeon intuit control rang motion fine tissu manipul capabl
visual characterist open surgeri simultan allow use small port
goal improv surgeri maxim number patient deriv benefit
competit environ although pioneer leader robotic-assist surgeri
face continu face competit form exist open surgeri convent
minim invas surgeri drug therapi radiat treatment emerg intervent surgic
approach success depend continu clinic technic innov qualiti reliabl
well educ hospit surgeon patient demonstr result associ da
vinci surgeri valu rel techniqu recent year numer compani
introduc product field robot surgeri made explicit intent enter field
robot surgeri verb surgic
decemb ownership exclus field-of-us licens
foreign patent foreign patent applic manufactur
market use class ii medic devic da vinci system govern extens
regul administ fda think act signific barrier entri competitor
da vinci system expens averag sell price million system also
take signific train time surgeon becom accustom result switch cost
high sinc earli mover robotic-assist surgeri high switch cost present
anoth barrier entri potenti new competitor
financi trend revenu account total revenu total revenu
billion higher prior year five-year cumul annual growth rate
compound-annual-growth-rate adjust earn per share ep vs five-year compound-annual-growth-rate
adjust ep free cash flow defin cash flow oper less
capit expenditur posit least past five year free cash flow million
addit compani typic maintain net cash posit compani invest substanti
amount research develop expens revenu
expect compani continu focu effort internally-gener innov maintain
technolog lead rather acquisit
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc octob technic indic
neutral
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
posit continu expect
compani sub-industri grow
posit macro environ addit
sub-industri mani product area
histor recession-resist
particularli equip use non-elect
procedur valuat continu high
industri driven expand margin
robust revenu growth compani
industri think lax food
drug administr fda
increas capabl technolog
enabl medic devic manufactur bring
innov product market faster
constant currenc basi expect
revenu sub-industri rise
high-single-digit low-double-digit
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent
year success effort
fda reduc approv time medic
devic time see price
pressur incess head wind medic
impact trade war appear mild
far medic equip compani
accord medic devic trade
septemb retaliatori tariff
billion us medic technolog export
although us chines govern
seek lower health care cost provid
equip manufactur insul
industri earlier commentari
medic devic manufactur suggest
impact trade war would manag
provid commentari impact
trade war earn
on-going threat state health
care system current us
administr continu attempt repeal
afford act stop
multipl time gather suffici
number vote pass variou repeal
replac bill recent on-going
lawsuit texa question
constitution
think import watch
mid-term elect novemb
health care appear import topic
hospit spend larg driver medic
equip sale robust
strong us economi
tax cut job act tcja individu
mandat roll think
hospit could see pressur lead
sale pressur medic equip
requir american health
insur without requir
expect lower number american
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
 health equip
sub-index increas vs rise
 composit index year
date septemb
increas composit
base index
five-year market price perform oct
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
ep estim world-wide da vinci procedur rose
driven gener surgeri world-wide urolog procedur drive sale
growth forecast howev note competitor
nr receiv fda approv senhanc robot system last
week think competit could elong sell cycl /jeffrey loo cfa
rais target price
split-adjust peer ep estim
split adjust also rais ep estim
look sale rise increas
procedur partial off-set slight declin revenu per procedur
also expect system revenu grow higher system placement
partial off-set lower sell price lower leas buy-out
ep estim report result octob /jeffrey
et cfra keep hold opinion share intuit surgic
inc rais target
peer forward ep estim slightli
mid-point rang ep vs
ahead estim ship da vinci system year
ago last quarter world-wide procedur grew robust hernia
repair colon procedur matur categori urolog
gynecolog stabil see continu solid procedur growth
instal base rose rais ep estim
et cfra keep hold opinion share intuit surgic
rais target peer
revis ep estim near mid-point
rang ep vs estim
sale rose procedur rose growth gener surgeri
world-wide urolog procedur ship da vinci system compar
year ago increas instal base year
ago encourag procedur growth isrg strongest sinc
see continu solid growth instal base expand /jeffrey
analyst research note compani news
et cfra maintain hold opinion share intuit
surgic inc rais target
above-p ep estim ep
vs higher estim anoth
out-perform rais ep ep
sale increas million world-wide da
vinci procedur increas year-over-year driven primarili
growth gener surgeri world-wide urolog procedur ship
da vinci surgic system quarter compar
first da vinci sp system ship quarter well
initi earli launch sureform stapler receiv
encourag feedback broaden appeal gener surgeon
tool like sureform stapler expect fulli launch
vessel sealer extend launch expect effort
like sustain continu adopt robot gener surgeri /kevin
et cfra maintain hold opinion share intuit
surgic inc rais target
above-p ep estim ep
vs higher estim impress
out-performance rais ep
ep sale increas
million procedur growth year-over-year driven primarili growth
 gener surgeri world-wide urolog procedur ship da
vinci surgic system quarter compar da
vinci sp isrg latest system approv use april
 food drug administr expect compani begin
ship da vinci sp sometim sp launch slow
gener clinic data custom feedback although view
isrg share price expens momentum appear continu drive
et cfra maintain hold opinion share intuit
surgic inc maintain target
above-p next ep estim ep
substanti beat expect due strong sale
million compar consensu estim million sale rose
year-over-year primarili due system revenu growth driven
system ship vs weaker us dollar
million revenu deferr world-wide procedur grew
growth us gener surgeri world-wide urolog procedur although
growth remain formid concern potenti impact
futur develop competit altern da vinci machin
execut risk launch new product inventori increas
seemingli excess level think may tie anticip product
launch rais ep estim ep
estim increas /kevin huang
et cfra keep hold opinion share intuit surgic
inc rais target price
peer ep estim near high
end five-year rang set ep ep
vs ahead estim sale grew da vinci
procedur rose driven gener surgeri procedur
surpass gynecolog largest specialti ship da vinci
system compar system year ago although anticip solid
increas procedur anticip growth moder
inc keep target peer
ep estim near high-end rang
ep vs ahead view rais
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
